EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD2AP is a potential prognostic biomarker of renal clear cell carcinoma

Can Chen, Jia Xu, Jie-Xin Zhang, Lin-Yuan Chen, Yu-Ang Wei, Wei-Ming Zhang, Peng-Fei Shao, Hua-Guo Xu iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Can Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Carcinoma, Kidney Neoplasms, Cytoskeletal Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province of China, the Priority Academic Program Development of Jiangsu Higher Education Institutions, National Key Clinical Department of Laboratory Medicine of China in Nanjing, Key laboratory for Laboratory Medicine of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD2‐associated protein (CD2AP) is a podocyte‐associated gene and its reduced expression is associated with the development of proteinuria and glomerulosclerosis. However, few studies have focused on the correlation between the expression and prognosis of CD2AP in renal clear cell carcinoma (ccRCC). Therefore, we aimed to assess the regulation of CD2AP expression and prognostic value in ccRCC.

Methods

Multiple databases were employed to examine the expression of CD2AP in ccRCC. RT‐qPCR, Western Blot and immunohistochemistry were used to validate CD2AP expression in different cell lines and tissue samples. Kaplan–Meier analysis and ROC curve analysis were performed on the predictive prognostic performance of CD2AP. COX regression was used to construct CD2AP‐related prognostic models. The TIMER and TISIDB databases were used to analyze the correlation of tumor‐infiltrating immune cells with gene expression, mutations, somatic copy number variation, and immune molecules. Mass spectrometry was used to detect methylation status of the promoter CpG site of CD2AP in multiple cells.

Results

We found that CD2AP expression was downregulated in ccRCC and its lower expression level was correlation with worse patient prognosis, higher tumor stage and grade and distant metastasis through analysis of databases, ccRCC cell lines and clinical tissue samples. Moreover, database and mass spectrometry techniques identified and validated cg12968598 hypermethylation as one of the key reasons for the downregulation of CD2AP expression. CD2AP expression was also associated with macrophage and neutrophil infiltration.

Conclusions

Taken together, our results suggest that CD2AP can be used as a diagnostic and prognostic biomarker in ccRCC patients and that DNA hypermethylation plays an important role in reducing CD2AP expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellCarcinomaKidney NeoplasmsCytoskeletal ProteinsAdaptor Proteins, Signal TransducingHumansDNA Copy Number VariationsPrognosisBiomarkers

Stichwörter der Autor:innen

CD2APDNA methylationccRCCrisk model

Substanzen

CD2-associated proteinBiomarkersCytoskeletal ProteinsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Laboratory Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Branch of National Clinical Research Center for Laboratory Medicine, Nanjing, China.
  • Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

ORCID-Profile: Hua-Guo Xu

Förderung

  • Natural Science Foundation of Jiangsu Province of China
  • the Priority Academic Program Development of Jiangsu Higher Education Institutions
  • National Key Clinical Department of Laboratory Medicine of China in Nanjing, Key laboratory for Laboratory Medicine of Jiangsu Province

Zitieren

APA

Chen, C., Xu, J., Zhang, J. X., Chen, L. Y., Wei, Y. A., Zhang, W. M., Shao, P. F., & Xu, H. G. (2024). CD2AP is a potential prognostic biomarker of renal clear cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.7055

Vancouver

Chen C, Xu J, Zhang JX, Chen LY, Wei YA, Zhang WM, et al. CD2AP is a potential prognostic biomarker of renal clear cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.7055

BibTeX
@article{Chen2024,
  author = {Chen, Can and Xu, Jia and Zhang, Jie-Xin and Chen, Lin-Yuan and Wei, Yu-Ang and Zhang, Wei-Ming and Shao, Peng-Fei and Xu, Hua-Guo},
  title = {CD2AP is a potential prognostic biomarker of renal clear cell carcinoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7055}
}
Kostenlos starten →